Ritholtz Wealth Management’s Krystal Biotech KRYS Stock Holding History

Ritholtz Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,500	Closed	-$270K	–	550
2021 Q1	$270K	Buy	+3,500	New	+$254K	0.02%	337
2020 Q4	–	Sell	-7,000	Closed	-$301K	–	418
2020 Q3	$301K	Sell	7,000 -3,200	-31%	-$139K	0.03%	209
2020 Q2	$422K	Buy	10,200 +1,200	+13%	+$57.7K	0.05%	129
2020 Q1	$389K	Buy	9,000 +1,000	+13%	+$52.3K	0.06%	90
2019 Q4	$443K	Hold	8,000	–	–	0.06%	89
2019 Q3	$278K	Sell	8,000 -11,409	-59%	-$510K	0.05%	110
2019 Q2	$782K	Hold	19,409	–	–	0.13%	53
2019 Q1	$639K	Buy	19,409 +5,000	+35%	+$118K	0.12%	64
2018 Q4	$299K	Buy	+14,409	New	+$302K	0.07%	95

Other funds holding KRYS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Ritholtz Wealth Management's KRYS Position: Q2 2021 in Review

Ritholtz Wealth Management sold out of Krystal Biotech (KRYS) in Q2 2021, closing a stake of 3,500 shares — an estimated $270K sold.

Ritholtz Wealth Management first reported a position in KRYS in Q4 2018 and held it in 9 quarters. The position peaked at $782K in Q2 2019. 113 funds tracked by Wall St. Rank hold KRYS as of Q2 2021.

Ritholtz Wealth Management reported no remaining Krystal Biotech position as of Q2 2021 after selling out during the quarter.
Ritholtz Wealth Management sold 3,500 Krystal Biotech shares in Q2 2021, an estimated $270K.
Ritholtz Wealth Management first reported a position in Krystal Biotech in Q4 2018 and held it in 9 quarters.
Ritholtz Wealth Management's Krystal Biotech position peaked at $782K in Q2 2019.
113 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2021.

Based on Ritholtz Wealth Management's 13F filing for Q2 2021, filed 20 Jul 2021.